Neurons transplanted into Parkinson’s-affected brains appear healthy after 14 years, according to research done at Harvard University and McLean Hospital and published June 5th 2014 in the journal Cell Reports.
For the study, dopamine neurons from fetal tissue were transplanted into the midbrains of adult patients with Parkinson’s disease. The neurons remained healthy for years. The findings suggest that transplanted neurons don’t degenerate over time as some had suggested and feared they would, which provides further rationale for pursuing stem cells as a source for transplant-ready dopamine neurons, the researchers maintain.
A release from the publisher quotes Ole Isacson as sying, “Our findings show a robust expression of dopamine transporters and a lack of abnormal mitochondrial morphology in implanted dopamine neurons for at least 14 years after transplantation. Our data therefore suggest that transplanted dopamine neurons can remain healthy and functional for decades.”
The tremors and other motor symptoms that characterize Parkinson’s disease result from the loss of dopamine-producing neurons in part of the midbrain. Neuron transplantation can replace failing neurons with healthy ones from a donor source, but there were questions about the health of those transplanted cells over time.
In the new study, Isacson and his colleagues examined dopamine neurons in five patients who had received fetal cell transplantation four to 14 years earlier. Their examination showed normal expression of dopamine transporters. The transplanted dopamine neurons also appeared to remain healthy and functional over time, with no signs of the degeneration characteristic of Parkinson’s disease.
Isacson said it is now clear that fetal cell transplantation has been beneficial for patients with Parkinson’s disease. Some patients have continued to improve clinically for decades without any medication for the disease at all. However, the therapeutic approach—in which a cell suspension derived from fetuses is injected directly into the relevant portion of the brain—has only been offered to a limited number of patients participating in clinical trials.
The researchers say they now hope to advance on alternative sources for dopamine neurons, particularly from induced pluripotent stem cells made from a patient’s own cells. “Our findings are extremely encouraging and timely for the field of regenerative medicine and for advancing stem cell-derived dopamine neuron transplantation as a restoration therapy for Parkinson’s disease,” Isacson said.
